Search results
Tumor mutations may not predict response to immuno | Newswise
Newswise· 3 days agoMay 22, 2024 – The number of mutations in the DNA of cancerous tumors may not be an indicator of how...
Aster Insights, ORIEN to Present Research Abstracts at the 60th ASCO Annual Meeting
CBS 47 Fresno· 3 days agoAster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced the company and members of the Oncology Research Information Exchange Network ...
Great Lakes Advisors LLC Has $1.11 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 2 days agoGreat Lakes Advisors LLC trimmed its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 50.8% during the fourth quarter, according to its most recent 13F filing with the ...
Principal Financial Group Inc. Trims Holdings in Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 5 days agoPrincipal Financial Group Inc. lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure ...
Swiss National Bank Has $3.57 Million Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 4 days agoSwiss National Bank lowered its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the ...
Exelixis (NASDAQ:EXEL) Now Covered by Stephens
ETF DAILY NEWS· 6 days agoStephens started coverage on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. The firm issued an equal weight rating and a $23.00 ...
Natixis Advisors L.P. Cuts Holdings in Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 6 days agoNatixis Advisors L.P. lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing ...